Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial.

about

Evaluation of brivaracetam: a new drug to treat epilepsy.Brivaracetam: First Global Approval.

P2860

Q38652806-6277330C-2422-44F1-8CE7-49CCF0512BD8 Q38743281-850E09C7-8B2D-4F9C-8980-910C9EE0892D

P2860

Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial.

Item

http://www.wikidata.org/entity/Q41877287

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Brivaracetam, a Novel Antiepil ...... ne Phase III Randomized Trial.

@en

type

Item

label

Brivaracetam, a Novel Antiepil ...... ne Phase III Randomized Trial.

@en

prefLabel

Brivaracetam, a Novel Antiepil ...... ne Phase III Randomized Trial.

@en

P1476

Brivaracetam, a Novel Antiepil ...... ne Phase III Randomized Trial.

@en

P2093

Alison M Pack

http://www.w3.org/2001/XMLSchema#string

P2860

Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.

Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.

Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.

SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

P304

196-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5698/1535-7597-14.4.196

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25170316

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4120388

http://www.w3.org/2001/XMLSchema#string

Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial.

about

P2860

P2860

Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932